4 results match your criteria: "Bordeaux University Hospital (Centre Hospitalier Universitaire)[Affiliation]"

Cardiac resynchronization therapy (CRT) is a recognized therapy for heart failure with altered ejection fraction and abnormal left ventricular activation time. Since the introduction of the therapy, a 30% rate of non-responders is observed and unchanged. The 12-lead ECG remains the only recommended tool for patient selection to CRT.

View Article and Find Full Text PDF

Use of Novel Electrogram "Lumipoint" Algorithm to Detect Critical Isthmus and Abnormal Potentials for Ablation in Ventricular Tachycardia.

JACC Clin Electrophysiol

April 2019

Electrophysiology and Ablation Unit, Bordeaux University Hospital (Centre Hospitalier Universitaire [CHU]), Pessac, France; Institut Hospitalo-Universitaire (IHU), LIRYC, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Université, Pessac- Bordeaux, France; Université Bordeaux, Institut National de la Santé et de la Recherche Médicale U1045, Bordeaux, France.

Objectives: This study reports the use of a novel "Lumipoint" algorithm in ventricular tachycardia (VT) ablation.

Background: Automatic mapping systems aid rapid acquisition of activation maps. However, they may annotate farfield rather than nearfield signal in low voltage areas, making maps difficult to interpret.

View Article and Find Full Text PDF

Background: Ventricular fibrillation (VF) storm after myocardial infarction (MI) is a life-threatening condition that necessitates multiple defibrillations. Catheter ablation is a potentially effective treatment strategy for VF storm refractory to optimal medical treatment. However, its impact on patient survival has not been verified in a large population.

View Article and Find Full Text PDF

The use of surface recordings to assess atrial fibrillation (AF) complexity is still limited in clinical practice. We propose a noninvasive tool to quantify AF complexity from body surface potential maps (BSPMs) that could be used to choose patients who are eligible for AF ablation and assess therapy impact. BSPMs (mean duration: 7 ± 4 s) were recorded with a 252-lead vest in 97 persistent AF patients (80 male, 64 ± 11 years, duration 9.

View Article and Find Full Text PDF